

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM493158

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MIDCAP FUNDING V TRUST	FORMERLY MidCap Financial V, LLC	01/06/2017	Trust: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Acerus Pharmaceuticals SRL		
<b>Street Address:</b>	Durants Business Centre		
<b>Internal Address:</b>	Suite B		
<b>City:</b>	Durants, Christ Church		
<b>State/Country:</b>	BARBADOS		
<b>Postal Code:</b>	BB17097		
<b>Entity Type:</b>	Sociedad De Responsabilidad Limitada: BARBADOS		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	77932590	COMPLEO TRT	
<b>Serial Number:</b>	85230489	TRI AIR DEPOSITION SYSTEM	
<b>Serial Number:</b>	85527122	TEFINA	
<b>Serial Number:</b>	86084664	NATESTO	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4156533775		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	4156533750		
<b>Email:</b>	wahector@venable.com, emgornall@venable.com		
<b>Correspondent Name:</b>	William A. Hector, Esq.		
<b>Address Line 1:</b>	Venable LLP		
<b>Address Line 2:</b>	101 California Street, Suite 3800		
<b>Address Line 4:</b>	San Francisco, CALIFORNIA 94111		
<b>ATTORNEY DOCKET NUMBER:</b>	140017436207 Sec Release		
<b>DOMESTIC REPRESENTATIVE</b>			
<b>Name:</b>	William A. Hector, Esq.		
<b>Address Line 1:</b>	Venable LLP		

CH \$115.00 77932590

<b>Address Line 2:</b>	101 California Street, Suite 3800
<b>Address Line 4:</b>	San Francisco, CALIFORNIA 94111
<b>NAME OF SUBMITTER:</b>	William A. Hector
<b>SIGNATURE:</b>	/William A. Hector/
<b>DATE SIGNED:</b>	10/09/2018
<b>Total Attachments: 12</b> source=Active_85911456_1_Acerus - USPTO Release#page1.tif source=Active_85911456_1_Acerus - USPTO Release#page2.tif source=Active_85911456_1_Acerus - USPTO Release#page3.tif source=Active_85911456_1_Acerus - USPTO Release#page4.tif source=Active_85911456_1_Acerus - USPTO Release#page5.tif source=Active_85911456_1_Acerus - USPTO Release#page6.tif source=Active_85911456_1_Acerus - USPTO Release#page7.tif source=Active_85911456_1_Acerus - USPTO Release#page8.tif source=Active_85911456_1_Acerus - USPTO Release#page9.tif source=Active_85911456_1_Acerus - USPTO Release#page10.tif source=Active_85911456_1_Acerus - USPTO Release#page11.tif source=Active_85911456_1_Acerus - USPTO Release#page12.tif	

**NOTICE OF RELEASE  
OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**

THIS NOTICE OF RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of January 6, 2017 (the "Effective Date"), by MIDCAP FUNDING V TRUST, successor to MidCap Financial V, LLC ("Grantee"), in favor of ACERUS PHARMACEUTICALS SRL (f/k/a Trimel BioPharma SRL) (the "Grantor").

WHEREAS, pursuant to the terms and conditions of that certain U.S. Intellectual Property Security Agreement dated as of July 16, 2014 (the "IP Security Agreement"), Grantor assigned, transferred and conveyed to Grantee, and granted to Grantee, a security interest in all of Grantor's right, title and interest in and to the Intellectual Property Collateral (as defined in the IP Security Agreement, the "Intellectual Property Collateral");

WHEREAS, the IP Security Agreement was recorded with the United States Patent and Trademark Office at Reel 5329, Frame 0592 and Reel 033416, Frame 0897; and

WHEREAS, Grantee has agreed to release its lien on all of the Intellectual Property Collateral, including but not limited to, (a) the trademarks and trademark applications listed on Schedule A hereto (collectively, the "Released Trademark Collateral"), and (b) the patents and patent applications listed on Schedule B hereto (collectively, the "Released Patent Collateral"), and together with the Released Trademark Collateral, the "Released IP Collateral").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

1. Grantee's mortgage, pledge, and hypothecation and lien on and security interest in the Released IP Collateral is hereby terminated and released.

2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantor, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Released IP Collateral. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.

3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantor. Grantee authorizes Grantor (or their agents) to file such documentation as is necessary to effect the releases of the Intellectual Property Collateral as provided herein.

4. Delivery of an executed signature page to this Release by facsimile or other electronic transmission shall be effective as delivery of a manually executed signature page of this Release.

[Signature page follows]


IN WITNESS WHEREOF, the Grantee has caused this Release to be duly executed as of the date first set forth above.

**GRANTEE:**

**MIDCAP FUNDING V TRUST**

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
Name: Maurice Amsellem  
Title: Authorized Signatory

**SCHEDULE A**

**Trademarks and Trademark Applications**

See attached.

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
COMPLEO TRT	Australia	1345400	1345400	Feb 12, 2010	Trimel Biopharma SRL	Registered Feb 12, 2010.	Renewal due Feb 11, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	Canada	1427288	1427288	Jan 30, 2009	Trimel Biopharma SRL	Allowed Feb 25, 2011.	File decl'n of use by July 30, 2014.	
COMPLEO TRT	China	8129778	8129778	Feb 24, 2010	Trimel Biopharma SRL	Registered Mar 21, 2011.	Renewal due Mar 21, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	European Community	008876741	008876741	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Renewal due Feb 11, 2020.	Subject to cancellation if not used for any 5 consecutive years from Registration.
COMPLEO TRT	Hong Kong	301543905	301543905	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Renewal due February 10, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	Japan	2010-009955	5456565	Feb 12, 2010	Trimel Biopharma SRL	Registered Dec 9, 2011.	Renewal December 9, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	New Zealand	819522	819522	Feb 11, 2010	Trimel Biopharma SRL	Registered Feb 11, 2010.	Feb 11, 2020	Subject to cancellation if not used for any 3 consecutive years from Registration.
COMPLEO TRT	US	77932590	77932590	Feb 10, 2010	Trimel Biopharma SRL	Allowed Oct 11, 2011.	File stm't of use by Oct 11, 2014	
Direct-Haler	Denmark	VA 2000 01998	VR 2000 03451	May 8, 2000	Direct-Haler A/S	Registered July 19, 2000	Renewal due July 19, 2020	
Direct-Haler	European Community	001751684	001751684	July 12, 2000	Direct-Haler A/S	Registered Sept 13, 2001.	Renewal due July 31, 2020	

48894613-3

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
Direct-Haler	India	1162704	1162704	Dec 30, 2002	Direct-Haler A/S	Registered March 23, 2007	Renewal due Dec 30, 2022	
Tri Air System & Design	Australia	1406483	1406483	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due Jan 31, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	Canada	1,493,393	1,493,393	Aug 6, 2010	Trimel Biopharma SRL	Allowed May 20, 2011.	File decl'n of use by Aug. 6, 2014. (extendible every 6 months until Aug 6, 2016)	
Tri Air System & Design	China	9109263	9109263	Jan 31, 2011	Trimel Biopharma SRL	Registered Feb 14, 2012.	Renewal due Feb 13, 2022.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	European Community	009698771	009698771	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due January 31, 2021.	Subject to cancellation if not used for any 5 consecutive years from Registration.
Tri Air System & Design	Hong Kong	301824877	301824877	Jan 31, 2011	Trimel Biopharma SRL	Registered Jan 31, 2011.	Renewal due May 30, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	Japan	2011-0058707	5411386	Jan 31, 2011	Trimel Biopharma SRL	Registered May 13, 2011.	Renewal due May 13, 2021.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	New Zealand	836534	836534	Jan 31, 2011	Trimel Biopharma SRL	Registered Aug 6, 2010.	Renewal due Aug 6, 2020.	Subject to cancellation if not used for any 3 consecutive years from Registration.
Tri Air System & Design	US	85230489	85230489	Jan 31, 2011	Trimel Biopharma SRL	Allowed Dec 27, 2011.	File str'n't of use by June 27, 2014. (extendible every 6 months until Dec 27, 2014)	
TBFINA	Barbados	81/29089		Jan 23, 2012	Trimel Biopharma SRL	Pending		

Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
TEFINA	US	85527122		Jan 27, 2012	Trimel Biopharma SRL	Allowed Aug 14, 2012.	File stm't of use by Aug 14, 2014. (extendible every 6 months until Feb 14, 2016)	
TEFINA	Canada	1,562,563		Jan 30, 2012	Trimel Biopharma SRL	Allowed Mar 8, 2013	File Decl'n of use by Jan 30, 2015. (extendible every 6 months until Jan 30, 2018)	
TEFINA	Australia	1502450	1502450	July 12, 2012	Trimel Biopharma SRL	Registered Issued on November 19, 2012.	Renewal due July 12, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	China	TBA	11211868	July 16, 2012	Trimel Biopharma SRL	Registered on December 7, 2013	Renewal due Dec 6, 2023	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	European Community	011035268	011035268	July 12, 2012	Trimel Biopharma SRL	Registered Issued on December 18, 2012	Renewal due July 12, 2022	
TEFINA	Hong Kong	302313143	302313143	July 12, 2012	Trimel Biopharma SRL	Registered Issued on December 14, 2012	Renewal due July 11, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	Japan	2012-56437	5533030	July 12, 2012	Trimel Biopharma SRL	Registered on November 2, 2012	Renewal due November 2, 2022	Subject to cancellation if not used for any 3 consecutive years from Registration.
TEFINA	New Zealand	962007	962007	July 12, 2012	Trimel Biopharma SRL	Registered	Renewal due Jan 23, 2022	Deemed Reg Date is January 23, 2012 Subject to cancellation if not used for any 3 consecutive years from Registration.
NATESTO	Barbados			Oct 2, 2013	Trimel Biopharma SRL	Pending		
NATESTO	United States	86/084,664		Oct. 7, 2013	Trimel Biopharma SRL	Pending		



Title	Country	Appl'n No.	Serial No.	Filing Date	Applicant	Status	Next Renewal Date	Comments
NATESTO	Canada	1,647,673		Oct. 8, 2013	Trimel Biopharma SRL	Pending		
NATESTO	Australia	1607228		Feb. 20, 2014	Trimel Biopharma SRL	Granted		
NATESTO	China			Mar. 3, 2014	Trimel Biopharma SRL	Pending		
NATESTO	European Community	012618931		Feb. 20, 2014	Trimel Biopharma SRL	Accepted; Opposition period expires June 28, 2014		
NATESTO	Hong Kong	992850		Feb. 20, 2014	Trimel Biopharma SRL	Application accepted June 20, 2014. Opposition period ends on September 19, 2014		
NATESTO	New Zealand	992850		Feb. 20, 2014	Trimel Biopharma SRL	Accepted; Opposition period expires June 28, 2014		
NATESTO	Japan	2014-13459		Feb. 24, 2014	Trimel Biopharma SRL	Pending		

**SCHEDULE B**

**Patents and Patent Applications**

See attached.

Bioadhesive Nasal Gel Related Owned Patent Applications

Patent Owner	Country Name	Name of Invention	Type of IP (Patent, Trademark, etc.)	Registration/Patent Application Number	Priority Date
Trimel BioPharma SRL	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,497	29-Jul-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,251	14-May-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,921	13-May-11
	United States of America	INTRANASAL 0.6% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,329	13-Feb-12
	United States of America	INTRANASAL 0.6% AND 0.72% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,445	14-May-12
	United States of America	INTRANASAL 0.45% AND 0.48% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,449	14-May-12
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,333	13-Feb-12
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,252	14-May-11
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,916	13-May-11
	United States of America	INTRANASAL 0.45% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,495	29-Jul-11
	United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/513,499	29-Jul-11
	United States of America	INTRANASAL 0.15% AND 0.24% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,450	14-May-12
	United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,903	13-May-11
	United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,254	14-May-11

48894613-3

America	TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER			
United States of America	INTRANASAL 0.15% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,335	13-Feb-12
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/486,266	14-May-11
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/518,913	13-May-11
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/598,336	13-Feb-12
United States of America	INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	13/471,452	14-May-12
United States of America	INTRANASAL TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	61/486,324	15-May-11
United States of America	INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	61/486,634	16-May-11
United States of America	INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM	Patent Application	14/082,032	15-Nov-13
United States of America	MALE TESTOSTERONE TITRATION METHODS, MALE INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING HYPOGONADISM AND TRT	Patent Application	61/729,138	21-Nov-12
United States of America	MALE TESTOSTERONE TITRATION METHODS, MALE INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING HYPOGONADISM AND TRT	Patent Application	61/729,406	22-Nov-12
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	14/080,695	14-Nov-13
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	61/729,304	21-Nov-12
United States of America	CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS	Patent Application	61/726,564	14-Nov-12
United States of America	CONTROLLED RELEASE NASAL TESTOSTERONE GELS, METHODS AND PRE-FILLED MULTI-DOSE APPLICATOR SYSTEMS FOR PERNASAL ADMINISTRATION	Patent Application	14/081,751	15-Nov-13
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/729,324	21-Nov-12
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	61/727,112	15-Nov-12
United	FEMALE INTRANASAL LOWER DOSAGE	Patent	61/726,570	14-Nov-12

States of America	STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Application		
United States of America	FEMALE INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER	Patent Application	14/080,732	14-Nov-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,739	17-Mar-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,737	17-Mar-13
United States of America	PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS FOR CONTROLLED RELEASE TOPICAL TESTOSTERONE GEL FORMULATIONS AND METHODS	Patent Application	61/802,388	16-Mar-13
United States of America	ONE- AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,354	15-Mar-13
United States of America	ONE- AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,724	17-Mar-13
United States of America	ONE- AND TWO-POINT TITRATION METHODS TO DETERMINE DAILY TREATMENT REGIMENS TO TREAT HYPOGONADISM OR MALE TESTOSTERONE DEFICIENCY WITH AN INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL	Patent Application	61/802,727	17-Mar-13
United States of America	METHODS OF TREATING HYPOGONADISM WITH TRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENTS	Patent Application	61/802,297	15-Mar-13

*Bioadhesive Nasal Gel Related Licensed Patents and Patent Applications*

Country	Type of IP (e.g., patent, TM, ©, mask work)	Registration/ Publication or Application Number	Filing Date/Expiration Date
USA	Granted Patent	5,756,071	17.05.1993
USA	Abandoned Patent Application	10/772,964	04.10.2004
USA	Granted Patent	8574622 (App 13/194,928)	30.07.2011
USA/A	Abandoned Patent Application	11/560,187	04.02.2004
USA	Abandoned Patent Application	12/796,165	08.06.2010
USA	Pending Patent Application - Notice of Allowance Granted	13/547,774	04-Feb-04
USA	Granted Patent	8609043 (App 13/567,878)	28-Dec-04
USA	Pending Patent	13/316,494	04-Feb-04

	Application - Notice of Allowance Granted		
USA	Pending Patent Application - Notice of Allowance Granted	13/194,853	04-Feb-04
USA	Abandoned Patent Application	13/194,663	28-Dec-04
USA	Abandoned Patent Application	13/152,882	28-Dec-04
USA	Abandoned Patent Application	12/418,917	10-Oct-06
USA	Pending Application	13/194,926	10-Oct-06
USA	Pending Application	14/322,319	02-Jul-14

*TriVair Related Owned Patents and Patent Applications*

Borrower Name/ Owner of IP	Country Name	Name/Identifier of IP	Type of IP (Patent/ TM/ Copyright/ Work)	Expiration Date
TBS	US	5797392	Owned Patent	22.01.2016
TBS	US	6811543	Owned Patent	26.05.2018
TBS	US	7661425	Owned Patent	30.06.2026
TBS	US	6648848	Owned Patent	26.05.2018